AB308 is a second investigational anti-TIGIT monoclonal antibody that is Fc-enabled. AB308 in combination with zimberelimab is currently being investigated in a Phase 1b study of people with advanced solid and hematologic malignancies.
The molecules and their uses are investigational. Arcus has not received approval from any regulatory
authority for any use globally, and the safety and efficacy of these molecules has not been established.